Gibson Dunn Advised LifeSci Capital as Financial Advisor in Quince Therapeutics’ Acquisition of Orphai Therapeutics and Concurrent Private Placement Financing

Firm News  |  May 20, 2026

---

Gibson Dunn advised LifeSci Capital as financial advisor in Quince Therapeutics, Inc.’s acquisition of Orphai Therapeutics Inc. and concurrent private placement financing.

The Gibson Dunn corporate team included partners Ryan Murr and Branden Berns.